secwatch.observer — SEC 8-K summary
======================================

Issuer:     VACCINEX, INC. (VCNX)
CIK:        0001205922
Form:       8-K
Filed at:   2022-08-08T23:59:59+00:00
Accession:  0001193125-22-214504
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccinex announces publication of Phase 2 SIGNAL HD study in Nature Medicine showing pepinemab slows cognitive decline
--------------------------------------------------------------------------------

- Phase 2 SIGNAL HD study results published in Nature Medicine (Aug 8, 2022) and Journal of Neuroinflammation.
- Pepinemab significantly improved cognition in early manifest HD patients (HD-CAB Index p=0.007).
- Pepinemab reduced caudate atrophy (p=0.017) and brain metabolic decline in FDG-PET.
- Treatment was well-tolerated with 5% treatment-emergent adverse events vs 9% placebo.
- Phase 1b/2a study of pepinemab in Alzheimer's disease initiated (NCT04381468).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1205922/000119312522214504/0001193125-22-214504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1205922/000119312522214504/d320536d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-214504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer